Book Value per Share: tuhurabio.com (HURA)

Public company logo of TuHURA Biosciences, Inc. (HURA)

The current financial position of TuHURA Biosciences, Inc. (HURA) is characterized by a cash burn of reserves due to primary drug trial costs, with the indicator standing at 0.29. The business model relies on outsourcing production and testing, which eliminates capital expenditures. The price visualization on GURU.Markets, which assists in the asset's baseline valuation, complements data on cell component logistics that ensure supply stability and high margins.

TuHURA (HURA) - Accounting Value per Share from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for TuHURA Biosciences Inc. (HURA)

- price and consensus price forecast:
Price Chart TuHURA|HURA - Fair Value Consensus
- market capitalization data:
Market Capitalization TuHURA Biosciences, Inc.|HURA - Enterprise Value
- book capitalization data:
Book Value per Share TuHURA Biosciences|HURA - Company Net Assets|Market Capitalization to Book Value Ratio tuhurabio.com|HURA - Company Total Assets
- debt and liquidity data:
Debt to Equity TuHURA Biosciences, Inc.|HURA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital TuHURA|HURA - Company Total Debt|Debts to Book Capitalization TuHURA Biosciences, Inc.|HURA - Long-Term Debt|Company Short-Term Debt TuHURA Biosciences
Analysis of all company metrics:tuhurabio.com, HURA
Manufactured product of TuHURA Biosciences Inc.

Book value per share determines the actual asset backing of investments by expressing the company's share of net capital in a single security. By analyzing the book value per share chart, one can track the impact of asset write-downs or share buybacks, which for the innovative visionary TuHURA Biosciences, Inc. (HURA) confirms the company's fundamental stability amid high investor loyalty to its oncology developments.

Competitor analysis for TuHURA Biosciences, Inc.

Net Assets per Single Share BeiGene Corp (ONC)|HALO - Accounting Value of a Share|RVMD: Book Value per Share|ascentage.com (AAPG) - Book Value per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Book Value per Share|WHWK - Accounting Value per Share|TScan - Accounting Value per Share|CSBR: Book Value per Share|Net Assets per Single Share xbiotech.com XBIT|CEL-SCI (CVM) - Accounting Value of a Share|Book Value per Share OSTX (OS Therapies Inc)|Net Asset Value per Share radiopharmtheranostics.com (RADX)|Accounting Value per Share Artiva Biotherapeutics, Inc.|Book Price of a Share adlainortye.com ANL|Accounting Value per Share VERU (Veru)|Book Value per Share Tempest Therapeutics Inc TPST|Book Value per Share Xilio (XLO)|Renovaro Inc. (RENB) - Accounting Value of a Share|MURA: Accounting Value per Share|KAPA (Kairos Pharma) - Book Value per Share|OKUR - Net Assets per Single Share|Accounting Value of a Share CytoMed|Book Value per Share CRIS|Book Value per Share apollomicsinc.com APLM|Accounting Value per Share Tharimmune, Inc.|Accounting Value of a Share Advanced Biomed Inc. ADVB|GNPX - Book Value per Share|CLDI - Net Assets per Single Share|Sunshine Biopharma, Inc. - Book Value per Share|XBIO (Xenetic Biosciences, Inc.) - Net Assets per Share|Net Assets per Single Share SLRX (Salarius Pharmaceuticals)|Net Asset Value per Share PPBT|AONC (American Oncology Network) - Net Assets per Single Share|Net Assets per Share BeiGene Ltd. (BGNE)|Checkpoint Therapeutics, Inc - Book Value per Share|Accounting Value per Share elevationoncology.com ELEV|Book Value per Share ICAD (iCAD Corp)|IKNA - Net Assets per Share|Book Value per Share NTBL|VIRX (Viracta Therapeutics, Inc.) - Net Asset Value per Share|Net Assets per Single Share MorphoSys Corp (MOR)|Equity per Share NAYA Biosciences Corp|Book Value per Share AAPGV (Ascentage Pharma Group)